Search Results
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).For
More news about: Ascletis Pharma Inc.
Dec 10, 2025, 04:15 ET 歌禮宣佈同類首創FASN抑制劑地尼法司他（ASC40）治療痤瘡的新藥上市申請獲中國國家藥品監督管理局受理
Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款在研小分子GLP-1R激動劑，既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法，用於長期體重管理；ASC36，一款每月一次皮下注射胰澱素受體激動劑多肽，ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽，ASC37，一款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Dec 10, 2025, 04:15 ET Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).For
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 04:40 ET 歌禮口服小分子GLP-1藥物ASC30在肥胖或超重受試者中進行的美國13周II期研究顯示經安慰劑校正後的體重下降高達7.7%，且胃腸道耐受性更佳
Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款在研小分子GLP-1R激動劑，既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法，用於長期體重管理；ASC36，一款每月一次皮下注射胰澱素受體激動劑多肽，ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽，ASC37，一款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).For
More news about: Ascletis Pharma Inc.
Nov 30, 2025, 05:15 ET Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
GLP-1R, GIPR, and GCGR triple peptide agonist, was discovered and optimized in-house utilizing Ascletis' Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). ASC37 in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR,
More news about: Ascletis Pharma Inc.
Nov 30, 2025, 05:15 ET 歌禮選定其首款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨床開發
香港2025年11月30日 /美通社/ -- 歌禮制藥有限公司（香港聯交所代碼：1672，簡稱「歌禮」）宣布已選定其首款口服GLP-1R/GIPR/GCGR[1]三靶點激動劑多肽ASC37口服片作為臨床開發候選藥物。歌禮預計將於2026年第二季度向美國食品藥品監督管理局（FDA）遞交ASC37口服片治療肥胖症的新藥臨床試驗申請（IND）。 ASC37口服片是本公司首款利用其專有的口服多肽遞送增強技術（Peptide Oral Transport ENhancement
More news about: 歌禮製藥有限公司
Nov 13, 2025, 17:31 ET ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
superior to those of current GLP-1R agonists. Preclinical studies on a novel combination therapy of ASC31 (a dual GLP-1R and GIPR peptide agonist) with ASC47 (a thyroid hormone receptor beta-selective small molecule targeting adipose tissue) revealed significantly greater
More news about: DelveInsight Business Research, LLP
Nov 12, 2025, 18:30 ET Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
B). -Combination of ASC47 and ASC31, a novel peptide agonist targeting both GLP-1R and GIPR, significantly outperformed both tirzepatide and ASC31 monotherapy in promoting weight loss, body fat loss, and muscle preservation in diet-induced obesity
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 19:10 ET 歌禮在2025年肥胖周（ObesityWeek®）報告ASC30口服片Ib期研究的完整分析、ASC30注射劑Ib期研究以及ASC31與ASC47聯合用藥臨床前研究
與 ASC31 （新型 GLP-1R 及 GIPR 雙靶點激動劑多肽）的聯合療法在減重、減脂及不減肌方面均顯著優於替爾泊肽單藥和 ASC31 單藥療法。
More news about: 歌禮製藥有限公司
Nov 04, 2025, 16:01 ET AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). MARITIME-1, a Phase 3 study of MariTide for chronic weight management, has completed enrollment of adults living with obesity
More news about: Amgen
Oct 29, 2025, 20:10 ET Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
excellent chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation with other peptides including ASC35, a GLP-1R/GIPR dual agonist. -Submission of an Investigational New Drug Application (IND) for ASC36 to the
More news about: Ascletis Pharma Inc.
Oct 27, 2025, 06:00 ET Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m., EST Abstract Title: GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice Presentation Time: November
More news about: Ascletis Pharma Inc.
Oct 12, 2025, 20:10 ET Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
and GIPR dual peptide agonist, was discovered and developed in-house utilizing Ascletis' Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. ASC35 was approximately 4-fold more potent than tirzepatide for both GLP-1R and GIPR in
More news about: Ascletis Pharma Inc.
Sep 21, 2025, 20:10 ET Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
subcutaneously administered GLP-1 receptor (GLP-1R)/GIP-receptor (GIPR) peptide agonist, and once-daily oral version of ASC47 in combination with once-daily oral ASC30. ASC35 is an in-house discovered and developed GLP-1R/GIPR peptide agonist. The pharmacokinetic data in non-human primates (NHP)
More news about: Ascletis Pharma Inc.
Aug 17, 2025, 20:15 ET Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
in-house developed GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual targeting peptide agonist drug candidate. ASC31 is an in-house discovered and developed novel peptide agonist targeting both GLP-1R and GIPR, which demonstrated a favorable pharmacokinetic profile in non-human primates
More news about: Ascletis Pharma Inc.
Aug 05, 2025, 16:01 ET AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR).In June, the underlying details from Part 1 of the Phase 2 study of MariTide and complete results from the primary analysis of the Phase 1
More news about: Amgen
Jun 23, 2025, 21:07 ET BrightGene presenteert positieve fase 2 gegevens voor de duale GLP-1R/GIPR agonist voor gewichtsbeheersing en type 2 diabetes, en preklinische gegevens voor een nieuw amylin-analoog tijdens de 85e wetenschappelijke sessies van de American Diabetes Association
De fase 2 gegevens benadrukken het best-in-class potentieel van de duale GLP-1R/GIPR agonist BGM0504 voor gewichtsbeheersing en het verminderen van metabool risico bij mensen met type 2 diabetes en overgewichtige, niet-obese individuen.De preklinische gegevens
More news about: Bright Gene
Jun 23, 2025, 21:05 ET BrightGene präsentiert positive Phase-2-Daten für den Dual-GLP-1R/GIPR-Agonisten zur Gewichtsregulation und Behandlung von Typ-2-Diabetes sowie präklinische Daten für ein neues Amylin-Analogon bei den 85 Wissenschaftlichen Sitzungen der American Diabetes Association
Die Phase-2-Daten heben das best-in-class Potenzial des Dual-GLP-1R/GIPR-Agonisten BGM0504 zur Gewichtsregulation und Reduktion des metabolischen Risikos bei Menschen mit Typ-2-Diabetes und übergewichtigen, nicht adipösen Personen hervorPräklinische Daten für
More news about: Bright Gene
Jun 23, 2025, 21:04 ET BrightGene présente des données positives de phase 2 pour son agoniste double GLP-1R/GIPR dans la gestion du poids et le diabète de type 2, ainsi que des données précliniques pour un nouvel analogue de l'amylin, lors de la 85 e édition des Sessions Scientifiques de l'American Diabetes Association
Les données de phase 2 mettent en évidence le potentiel « best-in-class » de l'agoniste double GLP-1R/GIPR BGM0504 pour la gestion du poids et la réduction des risques métaboliques chez les personnes atteintes de diabète de type 2 ainsi que chez les individus en surpoids non
More news about: Bright Gene
Jun 23, 2025, 21:03 ET BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individualsPreclinical data for BGM1812 supports further development
More news about: Bright Gene
Jun 23, 2025, 20:54 ET BrightGene Menyajikan Data Fase 2 yang Positif untuk Agonis Ganda GLP-1R/GIPR untuk Pengelolaan Berat Badan dan Diabetes Tipe 2 serta Data Praklinis untuk Analog Amylin Baru di Sesi Ilmiah ke-85 Asosiasi Diabetes Amerika
Data Fase 2 menyoroti potensi terbaik di kelasnya dari agonis ganda GLP-1R/GIPR BGM0504 untuk pengelolaan berat badan dan pengurangan risiko metabolik pada individu dengan diabetes tipe 2 dan individu kelebihan berat badan non-obesitasData praklinis untuk BGM1812
More news about: Bright Gene
Jun 23, 2025, 20:54 ET BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individualsPreclinical data for BGM1812 supports further development
More news about: Bright Gene
Jun 23, 2025, 14:31 ET RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
MariTideMariTide is a bispecific glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist being investigated for the treatment of obesity and Type 2 diabetes mellitus. As a pioneering peptide-antibody conjugate molecule with a
More news about: Amgen